Last reviewed · How we verify
Catgut
Catgut is a Small molecule drug developed by Universidad Científica del Sur. It is currently in Phase 1 development.
Catgut is a type of cord prepared from the natural fiber found in the walls of animal intestines, typically from sheep or goat intestines. It has been studied as an intervention in various clinical trials, including those for obesity, abdominal obesity, and persistent atrial fibrillation, where it is embedded at acupoints.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Catgut |
|---|---|
| Sponsor | Universidad Científica del Sur |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Suture Length Effects in Acupoint Implantation for Abdominal Obesity (NA)
- Comparison Between Maternal Complications of Chromic Catgut and Vicryl Rapid Sutures Used for Episiotomy Repair (NA)
- Thread Embedding vs. Electroacupuncture for Post-Stroke Aphasia (NA)
- Efficacy of Abdominal Catgut Embedding Combined With Auricular Acupressure Therapy for Obese Patients (NA)
- Comparison of Outcomes of Circumcision Via Open and Plastibell Methods (NA)
- Efficacy and Safety of Thread Embedding Acupuncture in Treating Gastroesophageal Reflux Disease (NA)
- Catgut Embedding in Acupoints on Treating Persistent Atrial Fibrillation After Catheter Ablation (NA)
- Properties of Absorbable and Nonabsorbable Suture Material in Dental Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Catgut CI brief — competitive landscape report
- Catgut updates RSS · CI watch RSS
- Universidad Científica del Sur portfolio CI
Frequently asked questions about Catgut
What is Catgut?
Who makes Catgut?
What development phase is Catgut in?
Related
- Manufacturer: Universidad Científica del Sur — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing